Overview

Studies have shown that the first treatment you receive for cancer is by far the most important. On average, lymphoma patients who begin their treatment at Seattle Cancer Care Alliance (SCCA) have better survival rates than those who started treatment elsewhere.

SCCA patients diagnosed with Hodgkin’s lymphoma receive state-of-the-art care from a team of specialists in this disease. SCCA was formed, in part, to bring promising new treatments to patients faster. For lymphoma patients, this means more treatment options than they might find elsewhere.

While we offer standard therapies, our particular expertise is in providing novel therapies to patients who may benefit from them. Many of our patients receive such therapies through clinical studies conducted at SCCA and its parent organizations, Fred Hutchinson Cancer Research Center and UW Medicine.
 
If you are newly diagnosed, our team can offer you options. If you’ve had initial treatment that did not cure your disease, we may have other options for you. And if you require a bone marrow transplant, you should know that the Fred Hutchinson Transplant Program at SCCA ranked ranked first in outcomes in a multi-year study by the National Marrow Donor Program that measured one-year survival rates of patients at 122 transplant centers nationwide.